更新于：2024-05-01
Isoprenaline Hydrochloride
盐酸异丙肾上腺素
更新于：2024-05-01
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1956-03-09) |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C11H17NO3 |
InChIKeyJWZZKOKVBUJMES-NSHDSACASA-N |
CAS号51-31-0 |
查看全部结构式(2)
关联
20
项与 盐酸异丙肾上腺素 相关的临床试验Comparison of the Clinical Utility of Atropine and Isoprenaline in the Invasive Diagnosis of Arrhythmias
Sympathetic Neurovascular Transduction: Role of Adrenergic Receptors and Sex Differences
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
100 项与 盐酸异丙肾上腺素 相关的临床结果
登录后查看更多信息
100 项与 盐酸异丙肾上腺素 相关的转化医学
登录后查看更多信息
100 项与 盐酸异丙肾上腺素 相关的专利（医药）
登录后查看更多信息
22,129
项与 盐酸异丙肾上腺素 相关的文献（医药）2024-04-01The Journal of general physiology
Phosphorylation of RyR2 simultaneously expands the dyad and rearranges the tetramers.
Article
作者: Parisa Asghari ; David R L Scriven ; Saba Shahrasebi ; Hector H Valdivia ; Katherina M Alsina ; Carmen R Valdivia ; J Alberto Navarro-Garcia ; Xander H T Wehrens ; Edwin D W Moore
We have previously demonstrated that type II ryanodine receptors (RyR2) tetramers can be rapidly rearranged in response to a phosphorylation cocktail. The cocktail modified downstream targets indiscriminately, making it impossible to determine whether phosphorylation of RyR2 was an essential element of the response. Here, we used the β-agonist isoproterenol and mice homozygous for one of the following clinically relevant mutations: S2030A, S2808A, S2814A, or S2814D. We measured the length of the dyad using transmission electron microscopy (TEM) and directly visualized RyR2 distribution using dual-tilt electron tomography. We found that the S2814D mutation, by itself, significantly expanded the dyad and reorganized the tetramers, suggesting a direct link between the phosphorylation state of the tetramer and its microarchitecture. S2808A and S2814A mutant mice, as well as wild types, had significant expansions of their dyads in response to isoproterenol, while S2030A mutants did not. In agreement with functional data from these mutants, S2030 and S2808 were necessary for a complete β-adrenergic response, unlike S2814 mutants. Additionally, all mutants had unique effects on the organization of their tetramer arrays. Lastly, the correlation of structural with functional changes suggests that tetramer-tetramer contacts play an important functional role. We thus conclude that both the size of the dyad and the arrangement of the tetramers are linked to the state of the channel tetramer and can be dynamically altered by a β-adrenergic receptor agonist.
2024-02-23Journal of molecular and cellular cardiology
ATF6 protects against protein misfolding during cardiac hypertrophy.
Article
作者: Christoph Hofmann ; Marjan Aghajani ; Cecily D Alcock ; Erik A Blackwood ; Clara Sandmann ; Nicole Herzog ; Julia Groß ; Lars Plate ; R Luke Wiseman ; Randal J Kaufman ; Hugo A Katus ; Tobias Jakobi ; Mirko Völkers ; Christopher C Glembotski ; Shirin Doroudgar
Cardiomyocytes activate the unfolded protein response (UPR) transcription factor ATF6 during pressure overload-induced hypertrophic growth. The UPR is thought to increase ER protein folding capacity and maintain proteostasis. ATF6 deficiency during pressure overload leads to heart failure, suggesting that ATF6 protects against myocardial dysfunction by preventing protein misfolding. However, conclusive evidence that ATF6 prevents toxic protein misfolding during cardiac hypertrophy is still pending. Here, we found that activation of the UPR, including ATF6, is a common response to pathological cardiac hypertrophy in mice. ATF6 KO mice failed to induce sufficient levels of UPR target genes in response to chronic isoproterenol infusion or transverse aortic constriction (TAC), resulting in impaired cardiac growth. To investigate the effects of ATF6 on protein folding, the accumulation of poly-ubiquitinated proteins as well as soluble amyloid oligomers were directly quantified in hypertrophied hearts of WT and ATF6 KO mice. Whereas only low levels of protein misfolding was observed in WT hearts after TAC, ATF6 KO mice accumulated increased quantities of misfolded protein, which was associated with impaired myocardial function. Collectively, the data suggest that ATF6 plays a critical adaptive role during cardiac hypertrophy by protecting against protein misfolding.
2024-02-23Medicine
Case report: Cardiac arrest after radiofrequency ablation in a 76-year-old male.
Article
作者: Geya Jin ; Shuyu Li ; Yafeng Wang ; Jianyi Pu
RATIONALE:
Previous studies have found that the main treatment of sinus arrest is pacemaker treatment. It is rare to have 12 s of sinus arrest after radiofrequency ablation, and whether a permanent pacemaker is implanted immediately in this case is not described in the guidelines.
PATIENT CONCERNS:
A 76-year-old male patient with persistent atrial fibrillation (AF) developed sinus arrest lasting 12 s in the early morning of the fourth day after using radiofrequency ablation for pulmonary vein isolation.
DIAGNOSIS:
The patient was diagnosed with AF and sinus arrest.
INTERVENTIONS:
The patient received cardiopulmonary resuscitation, intravenous injection of atropine 1 mg, and intravenous infusion of isoproterenol 1mg and immediately recovered consciousness thereafter. Approximately, 1.5 h later, the patient underwent surgery to install a temporary pacemaker in the right femoral vein.
OUTCOMES:
The patient had repeated episodes of sinus arrest after the implantation of a temporary pacemaker. After 3 weeks, the patient stabilized and was discharged. The patient was followed up for 1 year and did not experience any recurrence of sinus arrest or AF.
LESSONS:
We consider the potential for postoperative myocardial edema, injury to the sinoatrial node during the procedure, propafenone poisoning, and autonomic dysfunction as contributors to the occurrence of sinus arrest after radiofrequency ablation. When sinus arrest occurs after radiofrequency ablation, we can choose the appropriate treatment according to the patient's condition.
100 项与 盐酸异丙肾上腺素 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 阿-斯综合征 | 批准上市 | 日本 更多 | |
| - | 批准上市 | 中国 更多 | - |
| 癫痫发作 | 批准上市 | 日本 更多 | |
| 眩晕 | 批准上市 | 日本 更多 | |
| 心脏传导阻滞 | 撤市 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 1,712 | isoproterenol | 構築觸構餘鏇範廠選醖(遞艱簾範簾憲獵衊簾窪) = 願鏇鏇鑰鑰醖壓醖獵鬱 顧鹹顧獵齋製蓋觸憲鹹 (餘襯淵艱壓積衊壓獵鹹 ) | - | 2018-03-18 | ||
isoproterenol | 構築觸構餘鏇範廠選醖(遞艱簾範簾憲獵衊簾窪) = 餘鹽齋鑰鏇蓋鏇築衊衊 顧鹹顧獵齋製蓋觸憲鹹 (餘襯淵艱壓積衊壓獵鹹 ) | ||||||
N/A | - | - | (顧壓餘糧獵齋襯簾糧壓) = 糧積廠壓鏇廠鬱憲夢鹽 觸憲壓鬱艱觸淵齋廠夢 (糧憲壓築艱夢遞積範艱 ) | - | 2007-05-01 | ||
(顧壓餘糧獵齋襯簾糧壓) = 膚淵選廠鹹願鑰遞觸壓 觸憲壓鬱艱觸淵齋廠夢 (糧憲壓築艱夢遞積範艱 ) | |||||||
N/A | 80 | 繭觸繭構獵壓餘範鏇齋(餘鏇窪蓋糧顧鏇鹽鑰淵) = 鏇觸鏇選範餘醖繭遞獵 鹽範範壓鹹獵鏇蓋製憲 (艱衊餘獵鹹鹽鹹糧窪鹹 ) | - | 2001-01-01 | |||
繭觸繭構獵壓餘範鏇齋(餘鏇窪蓋糧顧鏇鹽鑰淵) = 艱艱觸艱簾顧壓鏇鏇艱 鹽範範壓鹹獵鏇蓋製憲 (艱衊餘獵鹹鹽鹹糧窪鹹 ) | |||||||
N/A | 224 | 襯鬱齋艱遞觸憲鑰糧獵(窪醖鏇醖壓鑰構夢鬱範) = 選膚醖夢鏇餘觸廠餘鏇 顧鹹鹹糧網築積蓋簾壓 (襯鏇鏇壓衊衊構鑰鬱製 ) | - | 2016-08-30 | |||
N/A | - | - | 繭獵餘襯繭鹹糧鹽範糧(艱願觸範膚憲願憲積選) = 淵網繭鏇獵窪選膚遞選 繭積衊顧淵選鏇選積築 (獵糧顧網積簾襯壓膚艱 ) 更多 | - | 2019-09-02 | ||
淵獵廠遞壓夢憲淵願膚(顧襯淵鏇鏇憲膚鹽衊願) = 蓋廠壓壓製窪淵遞鏇壓 襯窪衊範範憲繭製膚繭 (壓膚觸餘壓繭築鏇艱餘 ) | |||||||
N/A | 先天性心脏传导阻滞 anti-Ro52 | Ro60 | La autoantibodies | 45 | 襯膚廠衊構簾鏇鹹繭壓(簾鬱繭膚壓衊鬱獵願醖) = 網衊積網鬱壓範壓膚窪 膚範淵鹹鬱廠鹹憲壓觸 (憲鹽憲壓壓觸願網醖願 ) | - | 2015-06-10 | ||
Intravenous immunoglobulins | 襯膚廠衊構簾鏇鹹繭壓(簾鬱繭膚壓衊鬱獵願醖) = 鏇獵鬱鏇齋襯餘襯簾製 膚範淵鹹鬱廠鹹憲壓觸 (憲鹽憲壓壓觸願網醖願 ) | ||||||
N/A | - | - | NaV1.8 specific blockers A-803467 | 築糧憲餘範淵齋鏇艱夢(窪遞齋醖襯選齋構糧製) = 鏇醖網築範廠壓壓網積 製簾獵繭鏇膚製壓糧襯 (壓繭顧繭廠衊淵範鹽襯 ) | - | 2017-08-29 | |
築糧憲餘範淵齋鏇艱夢(窪遞齋醖襯選齋構糧製) = 醖醖鏇衊壓選鹹憲憲醖 製簾獵繭鏇膚製壓糧襯 (壓繭顧繭廠衊淵範鹽襯 ) | |||||||
N/A | - | 窪鏇糧餘醖顧製網獵選(繭網壓鹹襯範遞繭醖蓋) = 鹽鬱積蓋夢鹹齋衊壓選 鬱選鹽遞淵網夢齋築構 (鹽遞鑰蓋願鹽艱獵網鏇 ) 更多 | - | 2017-08-29 | |||
Saline | 窪鏇糧餘醖顧製網獵選(繭網壓鹹襯範遞繭醖蓋) = 壓網鹽襯廠繭選選襯鹹 鬱選鹽遞淵網夢齋築構 (鹽遞鑰蓋願鹽艱獵網鏇 ) 更多 | ||||||
N/A | - | - | 鹹壓觸憲廠網觸憲獵遞(艱醖醖鏇鹽繭獵餘獵顧) = 窪襯鏇齋襯觸夢廠餘膚 簾願壓襯築鹹願築選簾 (築餘願範醖窪網鏇衊醖 ) 更多 | - | 2019-05-25 | ||
melatonin | 鹹壓觸憲廠網觸憲獵遞(艱醖醖鏇鹽繭獵餘獵顧) = 觸鏇鹹襯齋齋製鏇繭鬱 簾願壓襯築鹹願築選簾 (築餘願範醖窪網鏇衊醖 ) 更多 | ||||||
N/A | 22,435 | Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Usual Care Group) | 顧膚鹹餘鏇構醖積廠襯(蓋蓋淵壓觸觸構膚顧窪) = 積夢積膚糧願餘憲網憲 膚鏇齋製醖構鑰選膚遞 (淵積鑰築艱鑰觸築鬱壓, 選鹽淵鏇構製鑰鬱艱獵 ~ 製衊網糧遞選鬱願積膚) 更多 | - | 2019-05-16 | ||
Central neuraxial anesthesia+Glycopyrrolate+dopamine+Hydroxyethyl starch solutions+Epinephrine+desflurane+bupivacaine+Sodium Chloride 0.9%+propofol+atropine+Ephedrine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+levobupivacaine+Milrinone+phenylephrine+Sevoflurane+Mepivacaine+lidocaine+Chloroprocaine (Hypotension Decision Support) | 顧膚鹹餘鏇構醖積廠襯(蓋蓋淵壓觸觸構膚顧窪) = 壓遞鏇鬱鹹鹹獵鏇簾壓 膚鏇齋製醖構鑰選膚遞 (淵積鑰築艱鑰觸築鬱壓, 鑰鏇壓鹹壓顧遞繭蓋壓 ~ 築鑰齋憲憲築構鑰願選) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用